 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
News Briefs Biotech Company to Slash AIDS Drug Price in AfricaDecember 18, 2002 Gilead Sciences announced it will cut the price of its AIDS drug Viread for all of Africa and 15 UN-designated "least-developed" countries elsewhere. The company will sell the drug at "no profit," charging only for production and distribution. Gilead will supply Viread directly to qualified treatment programs. The company will create a Web site to accept applications and hopes to begin drug shipments by the middle of next year. Applying programs will be evaluated based on their ability to sustain an effective treatment program and adequately prescribe and store the drug. Gilead spokesperson Amy Flood said Tuesday the company has not determined what Viread will cost in the developing nations. The drug costs $4,320 annually per patient in the United States. Back to other CDC news for December 18, 2002 Associated Press 12.18.02  This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. |
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
